An approach to personalized medicine: the BATTLE trialAuthor(s): Niels Reinmuth, Michael Thomas
In the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial designed in 2005, four agents against defined molecular targets were assigned to metastatic lung cancer patients based on predefined biomarkers. In this trial, it was demonstrated that a prospective biomarker-driven personalized therapeutic approach in lung cancer is feasible. In this article, preliminary results of this trial as well as the concept of biomarker-driven therapy of non-small-cell lung cancer patients will be summarized. As one of the results from this trial, re-biopsies of metastatic disease will become increasingly important and should be performed with acceptable risks for the patient, and combined with treatment options, whenever possible.